CD274 and non-small cell lung carcinoma: The current first-line (1 L) standard-of-care (SOC) therapy for KRASG12C-mutant NSCLC is a platinum-based chemotherapy usually combined with immune checkpoint inhibitors (ICIs), depending on the programmed death-ligand 1 (PD-L1) expression status.